MYOCARDIAL ISCHEMIA AND COMPONENTS OF OXIDATIVE STRESS IN DIABETES – AN ACCIDENTAL ASSOCIATION? CASE REPORT AND LITERATURE REVIEW

  • B. HUZUM “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Nicoleta DIMA “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Ana-Roxana GANCEANU-RUSU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Adelina PARLAPAN “Sf. Spiridon” County Clinical Emergency Hospital, Iasi, Romania
  • Andreea CLIM “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Cristina LAZAR “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • R. HILITEANU The State University of Physical Education and Sport, Chisinau, Republic of Moldova
  • Ionela Lacramioara SERBAN “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Abstract

The global epidemic of diabetes can be alarming and extremely severe. Diabetes, especially in type 2 cells, is officially recognized as a major and independent cardiovascular risk factor. We are presenting the case of a 55-year-old female diabetic patient, with postoperative status, admitted to the internal medicine clinic for polymorphic symptomatology and elevated blood pressure values at home. From an evolutionary point of view, the patient presents electrocardiographic and enzymatic dynamics, and the therapeutic approach was non-interventional. This case was particular due to the postoperative status, cardiovascular risk factors and important prognostic implications through pain perception disorders. The assessment of the overall cardiovascular risk is important to determine the optimal time to initiate the therapy, its intensity, and therapeutic targets. The role of the multidisciplinary team is essential in the complex management of the patient. The aim of this paper is to make a brief review of the role that endothelial dysfunction and oxidative stress have in diabetes and cardiovascular disease.

Author Biographies

B. HUZUM, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Morpho-functional Sciences (II)

Nicoleta DIMA, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)
“Sf. Spiridon” County Clinical Emergency Hospital, Iasi, Romania

Ana-Roxana GANCEANU-RUSU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)
“Sf. Spiridon” County Clinical Emergency Hospital, Iasi, Romania

Andreea CLIM, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Morpho-functional Sciences (II)
“Sf. Spiridon” County Clinical Emergency Hospital, Iasi, Romania

Cristina LAZAR, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Morpho-functional Sciences (II)

Ionela Lacramioara SERBAN, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Morpho-functional Sciences (II)

References

1. Emerging Risk Factors Collaboration, Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375(9733): 2215-2222.
2. Zellweger MJ. Prognostic significance of silent coronary artery disease in type 2 diabetes. Herz 2006; 31(3): 240-245.
3. Woodman RJ, Chew GT, Watts GF. Mechanisms, significance, and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy. Drugs 2005; 65(1): 31-74.
4. Kim J, Montagnani M, Koh KK, Quon MJ. Reciprocal Relationships Between Insulin Resistance and Endothelial Dysfunction: Molecular and Pathophysiological Mechanisms. Circulation 2006; 113(15): 1888-1904.
5. Newsholme P, Fernandes Cruzat V, Keane KN,et al. Molecular mechanisms of ROS production and oxidative stress in diabetes. Biochemical Journal 2016; 473: 4527-4550.
6. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
7. Wilkinson IB, Franklin SS, Cockcroft JR. Nitric Oxide, and the regulation of large artery stiffness. Hypertension 2004; 44: 112-116.
8. Ma J, Nakagawa Y, Kojima I, Shibata H. Prolonged insulin stimulation down-regulates GLUT4 through oxidative stress-mediated retromer inhibition by a protein kinase CK2- dependent mechanism in 3T3-L1 adipocytes. J Biol Chem 2013; 298: 133e42.
9. Walton EL. Oxidative stress and diabetes: Glucose response in the cROSsfire. Biomedical Journal 2017; 40(5): 241-244.
10. Glovaci D, Fan W, Wong ND. Epidemiology of Diabetes Mellitus and Cardiovascular Disease. CurrCardiol Rep 2019; 21(4): 21.
11. Hadi HA, Suwaidi JA. Endothelial Dysfunction in diabetes mellitus. Vasc Health Risk Manag 2007; 3(6): 853-876.
12. Su JB. Vascular endothelial dysfunction and pharmacological treatment. World J Cardiol 2015; 7: 719-741.
13. Gage MC, Yuldasheva NY, Viswambharan H, et al. Endothelium-specific insulin resistance leads to accelerated atherosclerosis in areas with disturbed flow patterns: a role for reactive oxygen species. Atherosclerosis 2013; 230(1): 131-139.
14. WidLansky ME, Gokce N, Keaney JF, Vita JA.The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003; 42(7): 1149-1160.
15. Maranduca MA, Serban IL, Nicoleta D, et al. Cardiovascular and metabolic comorbidities-therapeutic difficulties. Case report. Rev Med Chir Soc Med Nat Iasi 2018; 122 (2): 304-308.
16. Halim M, Halim A. The effects of inflammation, aging and oxidative stress on the pathogenesis of diabetes mellitus (type 2 diabetes). Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2019; 13: 1165-1172.
17. Tanase DM, Gosav EM, Costea CF, et al. intricate relationship between type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR) and Nonalcoholic Fatty Liver Disease (NAFLD). J Diabetes Res 2020: 3920196
18. Barzilay JI, Freed Land ES. Inflammation and its relationship to insulin resistance, type 2 diabetes mellitus and endothelial dysfunction Review. Metabolic syndrome and related disorders 2003; 1(1): 54-67.
19. Triggle CR, Ding H, Anderson TJ. The endothelium in health and disease; A discussion of the con-tribution of non-nitric oxide endothelium-derived vasoactive mediators to vascular homeostasis in normal vessel and in type II diabetes. Mol Cell Biochem 2004; 263: 21-27.
20. Levine TB, Levine AB. The endothelium and nitric oxide. Metabolic syndrome and cardiovascular disease 2006; 1: 173-210.
21. Chenn J, Ye Z, Xiu-fen W. Nitric oxide bioavailability dysfunction involves in atherosclerosis. Biomedicine & Pharmacotherapy 2018; 97: 423-428.
22. Maranducă MA, Tarniceriu CC, Carasevici E, Cojocaru E. Interaction between angiotensin II, hyper-tension, and inflammation in rat kidney. Rev Med Chir Soc Med Nat Iasi 2015; 119(3): 791-797.
23. Jamwal S, Sharma S. Vascular endothelium dysfunction: a conservative target in metabolic disorders. Inflamm Res 2018; 67(5): 391-405.
24. Hamilton SJ, Watts GF. Endothelial Dysfunction in Diabetes. Pathogenesis, Significance, and Treatment. Rev Diabet Stud 2013; 10: 133-156.
25. Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol 2018; 17(1): 121.
26. Odegaard AO, Jacobs DR Jr, Sanchez OA, et al. Oxidative stress, inflammation, endothelial dys-function, and incidence of type 2 diabetes. Cardiovasc Diabetol 2016; 24: 15-51.
27. Kannel WB, McGee DL. Diabetes and Cardiovascular Disease: The Framingham Study. JAMA 1979; 241(19): 2035-2038.
28. Khafaji HA, Suwaidi JM. Atypical presentation of acute and chronic coronary artery disease in diabetics. World J Cardiol 2014; 6(8): 802-813.
29. Janand-Delenne B, Savin B, Habib G, et al. Silent myocardial ischemia in patients with diabetes: who to screen. Diabetes Care 1999; 22(9): 1396-1400.
30. Maranduca MA, Cojocaru E, Carasevici E. Correlations between arterial hypertension induced by angiotensin II and systemic inflammation in rat.Rev Med Chir Soc Med Nat Iasi 2016; 120(1): 77-82.
31. Tanase DM, Gosav EM, Neculae E, et al. Role of Gut Microbiota on Onset and Progression of Mi-crovascular Complications of Type 2 Diabetes (T2DM) Nutrients 2020; 12: 3719.
32. Hadaegh F, Ehteshami-Afshar S, Hajebrahimi MA, et al. Silent coronary artery disease and incidence of cardiovascular and mortality events at different levels of glucose regulation results of greater than a decade follow-up Int J Cardiology 2015; 182: 334-339.
33. KindLer M, Wanner PM, Filipovic M Cardiac risk in non-cardiac surgery: A review Trends in Anes-thesia and Critical Care 201821: 6-12.
34. Lozneanu L, Cojocaru E, Giusca SE, Carauleanu A, Caruntu ID Lesser-Known Molecules in Ovarian Carcinogenesis Biomed Res Int 2015, Article ID 321740.
35. ***2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management European Heart Journal 201435: 2383-2431.
36. Radico F, Cicchitti V, Zimarino M, et al Angina Pectoris and Myocardial Ischemia in the Absence of Obstructive Coronary Artery Disease: Practical Considerations for Diagnostic Tests JACC Cardiovasc Interv 2014; 7(5): 453-463.
Published
2020-12-23
Section
INTERNAL MEDICINE - PEDIATRICS